What is Insulet?
Insulet is a diabetes device technology company serving providers, payers, patients, labs, hospitals, researchers, or life-sciences commercial teams.
- Category
- Diabetes device technology
- Headquarters
- Acton, MA
- Founded
- See company profile and filings
- Employees
- Mid-market / scaled operating company
- Total funding
- Public company
- Status
- Public company; Nasdaq: PODD
What is Insulet?
Insulet is a diabetes device technology company headquartered in Acton, MA.
Insulet operates in diabetes device technology and has reached a scaled mid-market profile rather than an early startup footprint. Its official site and investor/company materials position the business around Omnipod 5, Omnipod DASH, PodderCentral, with customers using the company for repeatable operating workflows rather than one-off projects.
For sellers, Insulet is useful to profile because the buying center is large enough to include specialized finance, IT, operations, procurement, and line-of-business owners. The company status is Public company; Nasdaq: PODD, so the best live signals are current company announcements, investor materials where available, hiring patterns, product launches, and partner ecosystem activity.
What does Insulet offer?
Insulet's profile centers on Omnipod 5, Omnipod DASH, PodderCentral, Automated insulin delivery.
- Omnipod 5· Diabetes device technology
- Omnipod DASH· Diabetes device technology
- PodderCentral· Diabetes device technology
- Automated insulin delivery· Diabetes device technology
- Diabetes data· Diabetes device technology
- International distribution· Diabetes device technology
How does Insulet make money?
Insulet makes money through commercial activity tied to diabetes device technology.
Insulet monetizes through the commercial model common to diabetes device technology: a mix of product sales, subscriptions, usage, services, channel programs, or transaction volume depending on the operating unit. Public list pricing is not always available, so enterprise buyers usually evaluate packaging, contract scope, geographic coverage, implementation services, and support commitments.
The practical growth levers are account expansion, new product attach, channel reach, retention, and operational efficiency. For outbound teams, that means relevant sales angles usually connect to productivity, integration, compliance, data quality, margin improvement, customer experience, or faster execution across distributed teams.
Who leads Insulet?
Insulet's named executives should be verified on the official leadership or investor-relations page before outreach.
- Insulet executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Insulet finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, and budget discipline.
- Insulet technology or operations leadershipTechnology, product, operations, or security leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operational-improvement purchases.
How do you contact Insulet's leadership?
Insulet should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.insulet.comHow is Insulet funded?
Insulet's current status is Public company; Nasdaq: PODD.
Insulet's current capital profile is best understood through its current status: Public company; Nasdaq: PODD. If the company is public, the relevant financing signals are annual reports, quarterly results, debt disclosures, buybacks, acquisitions, and capital allocation commentary rather than venture rounds.
If the company is private or recently acquired, the important seller signal is ownership context: sponsors or strategic owners often push standardization, operating metrics, procurement discipline, and integration work. In either case, budget timing should be inferred from current company announcements, earnings materials, product launches, hiring, and strategic initiatives rather than stale funding databases.
How did Insulet get here?
Insulet's history should be read through founding, scale-up, public/private ownership, and current product or market focus.
- FoundingInsulet is foundedThe company begins building in diabetes device technology.
- Scale-upCommercial footprint expandsInsulet broadens its product, customer, or geographic reach.
- Capital marketsPublic company; Nasdaq: PODDOwnership and financing context shapes procurement, reporting, and operating priorities.
- 2025Mid-market operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, current status, and public source references.
Who are Insulet's competitors?
Insulet competes with larger platform incumbents and focused specialists in diabetes device technology.
- MedtronicGlobal medical-technology incumbent with broad device and care-management scale.
- Boston ScientificLarge medical-device company competing across interventional specialties.
- AbbottHealthcare company with diagnostics, diabetes care, devices, and nutrition scale.
- Johnson & Johnson MedTechLarge medtech and pharmaceutical incumbent with global commercial reach.
- StrykerOrthopedics, neurotechnology, and surgical equipment competitor with hospital relationships.
Insulet — frequently asked questions
